Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer
NCT05728268Phase 2Recruiting
- Sponsor
- Shantou Central Hospital
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, epirubicin, cyclophosphamide in breast cancer, sponsored by Shantou Central Hospital. Started Aug 2021; status: recruiting.
02
Drugs
paclitaxelepirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05728268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05728268.